Navigation Links
DNA Therapeutics Reports a Novel Mechanism of Action and a,Biomarker of its Lead Molecule Dbait That Open an Innovative,Pathway-Targeting in Molecular Cancer Therapy

EVRY, France, April 12, 2007 /PRNewswire/ -- DNA Therapeutics S.A. an emerging pharmaceutical company specialized in innovative cancer therapy announces today the elucidation of a new mechanism of action and the identification of a biomarker of its first-in-class antitumoral lead molecule Dbait. It will be presented at the forecoming American Association for Cancer Research annual meeting 2007. Its abstract is now available online. The presentation itself will be available from April 16th onwards at http://www.dna-therapeutics.com/doc/File/pdf/AACR2K7.pdf

Background: Most of the cancer therapies induce directly or indirectly DNA double strand breaks (DSBs), but unfortunately cells possess DNA repair complexes specialized in repairing these lethal lesions, which are responsible of lessened efficacy, or refractoriness of classical therapies.

A new family of anticancer drugs, named short inhibiting DNA (siDNA), has been designed by DNA Therapeutics' scientific founder team to inhibit these repair activities. The first lead, named Dbait, mimics DSBs, diverts DSB repair system from their primary objective, and facilitates cancer cells killing by traditional therapies.

The proof of concept work was presented last November at the 18th EORTC-NCI-AACR Symposium "Molecular Targets and Cancer Therapeutics" (Prague): the median survival of nude mice grafted with human tumor cell lines treated by intra-tumoral injection of Dbait, in association with radiotherapy, is significantly increased in a dose-dependent manner. MRI and cytology analysis of tumors shows that Dbait strongly enhances irradiation-induced necrosis and apoptosis.

New finding: The present study aims at deciphering the underlying mechanism of action of Dbait at molecular and cellular levels, and in particular its impact on DSB repair foci organi
'"/>




Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care

Post Your Comments:
(Date:11/25/2009)...ire/--Reportlinker.comannouncesthatanewmarketresea...nagement-GlobalTrends ,, http://www.reportli...html ,, Widespreadavailabilityofgenericdrugs,e...rugshaveacceleratedthepaceofgrowthinthepainmanagem...recontinuetoshapedemandforservices,drugsanddevices...
(Date:11/25/2009)...NEY,Nov.25/PRNewswire-FirstCall/--HeartWareInterna...orandprovideroflessinvasive,miniaturizedcirculator...dvancedheartfailure,todayannouncedthatitisschedule...affrayHealthCareConferenceat8:00amESTonWednesday,D...PalaceHotel,December1-2. ,, AlivewebcastoftheCo...
(Date:11/24/2009)...wswire/-- ,, WHAT:RomHoubens,aBelgianmanthought...wasactuallyfullyconsciousandawakeduringthattimeand...oxEyeMaxwasfeaturedinthesegmenttoillustratehowpeop...communication. ,, WHEN:GoodMorningAmerica-- Tue...ch.com ,, WHO:RomHoubenswasanengineeringstu...
Breaking Medicine Technology:Reportlinker Adds Pain Management - Global Trends 2Reportlinker Adds Pain Management - Global Trends 3Reportlinker Adds Pain Management - Global Trends 4Reportlinker Adds Pain Management - Global Trends 5DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 13428 1InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 13428 2InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 13428 3InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 13428 4InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 13428 5InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 13428 6InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 13428 7InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 13428 8InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 13428 9InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 13428 10InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 13428 11InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 13428 12InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 13428 13InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 13428 14InterMune Reports Second Quarter 2009 Financial Results and Business Highlights 13428 15OncoGenex Reports Second Quarter 2009 Financial Results 13426 1OncoGenex Reports Second Quarter 2009 Financial Results 13426 2OncoGenex Reports Second Quarter 2009 Financial Results 13426 3OncoGenex Reports Second Quarter 2009 Financial Results 13426 4OncoGenex Reports Second Quarter 2009 Financial Results 13426 5OncoGenex Reports Second Quarter 2009 Financial Results 13426 6OncoGenex Reports Second Quarter 2009 Financial Results 13426 7Vectibix 28R 29 in Combination With Chemotherapy Significantly Improved Progression Free Survival in First Line Metastatic Colorectal Cancer 4834 1Vectibix 28R 29 in Combination With Chemotherapy Significantly Improved Progression Free Survival in First Line Metastatic Colorectal Cancer 4834 2Vectibix 28R 29 in Combination With Chemotherapy Significantly Improved Progression Free Survival in First Line Metastatic Colorectal Cancer 4834 3Vectibix 28R 29 in Combination With Chemotherapy Significantly Improved Progression Free Survival in First Line Metastatic Colorectal Cancer 4834 4Vectibix 28R 29 in Combination With Chemotherapy Significantly Improved Progression Free Survival in First Line Metastatic Colorectal Cancer 4834 5Vectibix 28R 29 in Combination With Chemotherapy Significantly Improved Progression Free Survival in First Line Metastatic Colorectal Cancer 4834 6Vectibix 28R 29 in Combination With Chemotherapy Significantly Improved Progression Free Survival in First Line Metastatic Colorectal Cancer 4834 7Vectibix 28R 29 in Combination With Chemotherapy Significantly Improved Progression Free Survival in First Line Metastatic Colorectal Cancer 4834 8
(Date:11/25/2009)... EDINA,Minn.,Nov.25/PRNewswire-USNewswire/--Whenmo...Butachiropractorcanalsogivepatientsthehelptheyneed...ereyourjaw(mandible)contacts/connectswithyourskull...tedwithTMJdysfunctionarepainwithchewing,clickingor...mTMJdysfunctionincluding:headaches,fatigue,sleepdi...
(Date:11/25/2009)... TORONTO,Nov.25/PRNewswire/-SentinelleMedicalInc.,...ualizationsoftwarelaunchesasuiteofnewleadingedgecl...wareplatformatthisyear,sRadiologicalSocietyofNorth...009(Booth5800,HallA).Theapplicationsleveragetheuni...izedMRIimagingcoilsandsupportmultipleimagingmodali...
(Date:11/25/2009)... SANFRANCISCO,Nov.25/PRNewswire/--TheBayAreaAirQua...nter Spare the Air Alert forThursday...irelogsoranyothersolidfuel,bothindoorsandoutdoors....airqualitytomorrow,"saidJackBroadbent,executiveoff...orespectthehealthoftheirneighborsandfellowcommunit...
(Date:11/25/2009)...ortuitous discovery that grew out of a collaborati...entially offer hope to the nearly 10 million Ameri... , Also known as hardening of the arteries, p...rculatory problem in which narrowed arteries reduc...ered a red flag for vascular disease, heart attack...
(Date:11/25/2009)... Evaluation and treatment clinic... Woodstock (Vocus) November 25, 2009 -- Centeg... vaccines and H1N1 vaccine shots at four Centegra ...er shipment of vaccine has arrived. The clinics ar... and McHenry and will be open as follows: , &n...
Breaking Medicine News(10 mins):Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4
...wn to have a genetic predisposition. //This study ... DNA double helix. Collaborated Research is b...de Hospital campus of The Feinstein Institute for ... that vary dramatically in symptoms and severity a...
...greement to deliver a fast, efficient new electron...ve as a win for patients and doctors alike. T...irst organisation to sign up to deliver the new sy...mmittee on Information Technology, Dr Peter Garcia...
...and disappointment on hearing the news about a Lib...ences on five Bulgarian nurses and one Palestinian...reds of children with HIV. George Bush has exp...urses would be fully supported by him. The US ...
...IDF) Diabetes Atlas released early December in Sou...hest in India.// But China overtakes India in the ...T). The Atlas, third in a series that began i... is predicted to increase dramatically over the ne...
...read to many different sites often do not have man...to tolerate the doses of treatment they would need... Hope and St. Jude Children's Research Hospital ma...trate chemotherapeutic drugs predominately at tumo...
... research centre is being planned at the Pune-base...eat diseases//, a general says. "Stem cell ther...edicine. It will be the futuristic treatment repla...e disease and various other diseases can be cured,...
Other Medicine News:Health News:Research on Bipolar Disorder Launched 2Health News:Researchers Find Stem-cell Therapy Effective in Targeting Metastatic Cancer 2Health News:Military College to Set Up Stem Cell Research Centre 2
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
Medicine Products: